Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders
AssigneeARYx Therapeutics, Inc.
InventorsIan Irwin, Monica Palme, Cyrus Becker, Pascal Druzgala
Life of this patent
Estimating the term…
Abstract
The subject invention provides stereoisomeric compounds of formula (X): wherein the variables are as defined herein, and compositions for the safe and effective treatment of various gastrointestinal disorders including, but not limited to, gastroparesis, gastroesophageal reflux and related conditions. The compounds of the subject invention are also useful in treating a variety of conditions involving the central nervous system.
Claims12
A method of treating a gastrointestinal disorder responsive to a 5HT4 receptor agonist comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound of the formula
- and pharmaceutically acceptable salts thereof, wherein
- the bonds at positions 3 and 4 are cis relative to each other;
- R1 is halogen;
- R2 is amino, NH(C1-C4 alkyl) or N(C1-C4 alkyl)(C1-C4 alkyl);
- R3 is OH or C1-C4 alkoxy;
- R4 is H or methyl;
- and
- R5 is —O—C3-C8 cycloalkyl, —O-heterocycloalkyl or heterocycloalkyl, wherein the heterocycloalkyl portion of the —O-heterocycloalkyl or heterocycloalkyl is aza-bicyclo-octyl, aza-bicyclo-nonyl, aza-bicyclo-decyl, piperidinyl, piperazinyl, or pyrrolidinyl, wherein
- the piperidinyl, piperazinyl, and pyrrolidinyl groups are unsubstituted or substituted at one or two positions with groups that are independently C1-C4 alkyl, C1-C4 alkoxy, halogen, C1-C4 haloalkyl, C1-C4 haloalkoxy, hydroxyl, hydroxy C1-C4 alkyl, amino, —NH(C1-C4 alkyl), —N(C1-C4 alkyl)(C1-C4 alkyl), —(C0-C6 alkyl)-C(O)R11, or NO2, and wherein
- the aza-bicyclo-octyl, aza-bicyclo-nonyl, and aza-bicyclo-decyl nitrogen is optionally substituted with methyl or ethyl;
- R9 at each occurrence is independently H or C1-C4 alkyl;
- R11 is C1-C6 alkoxy, optionally substituted with 1 or 2 groups that are independently C1-C4 alkoxy, amino, —NH(C1-C6 alkyl), —N(C1-C6 alkyl)(C1-C6 alkyl), —(C0-C6 alkyl)-C(O)N(R9)-heterocycloalkyl, O-heterocycloalkyl, or heterocycloalkyl, wherein the heterocycloalkyl is pyrrolidinyl, piperidinyl, piperazinyl, or morpholinyl, wherein the heterocycloalkyl groups are optionally substituted with 1, 2, or 3 groups that are independently halogen, C1-C6 alkyl, C1-C6 alkoxy, hydroxy, hydroxy C1C6 alkyl, C1-C6 alkoxycarbonyl, —CO2H, CF3, or OCF3;
- and
- R20 is C1-C6 alkoxy (preferably C1-C4 alkoxy, more preferably methoxy), or OH.
A method of treating a gastrointestinal disorder selected from the group consisting of gastroesophageal reflux disease (GERD), emesis, dyspepsia, gastroparesis, constipation, intestinal pseudo-obstruction, post-operative ileus comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound of the formula
- and pharmaceutically acceptable salts thereof, wherein
- the bonds at positions 3 and 4 are cis relative to each other;
- R1 is halogen;
- R2 is amino, NH(C1-C4 alkyl) or N(C1-C4 alkyl)(C1-C4 alkyl);
- R3 is OH or C1-C4 alkoxy;
- R4 is H or methyl;
- and
- R5 is —O—C3-C8 cycloalkyl, —O-heterocycloalkyl or heterocycloalkyl, wherein the heterocycloalkyl portion of the —O-heterocycloalkyl or heterocycloalkyl is aza-bicyclo-octyl, aza-bicyclo-nonyl, aza-bicyclo-decyl, piperidinyl, piperazinyl, or pyrrolidinyl, wherein
- the piperidinyl, piperazinyl, and pyrrolidinyl groups are unsubstituted or substituted at one or two positions with groups that are independently C1-C4 alkyl, C1-C4 alkoxy, halogen, C1-C4 haloalkyl, C1-C4 haloalkoxy, hydroxyl, hydroxy C1-C4 alkyl, amino, —NH(C1-C4 alkyl), —N(C1-C4 alkyl)(C1-C4 alkyl), —(C0-C6 alkyl)-C(O)R11, or NO2, and wherein
- the aza-bicyclo-octyl, aza-bicyclo-nonyl, and aza-bicyclo-decyl nitrogen is optionally substituted with methyl or ethyl;
- R9 at each occurrence is independently H or C1-C4 alkyl;
- R11 is C1-C6 alkoxy, optionally substituted with 1 or 2 groups that are independently C1-C4 alkoxy, amino, —NH(C1-C6 alkyl), —N(C1-C6 alkyl)(C1-C6 alkyl), —(C0-C6 alkyl)-C(O)N(R9)-heterocycloalkyl, O-heterocycloalkyl, or heterocycloalkyl, wherein the heterocycloalkyl is pyrrolidinyl, piperidinyl, piperazinyl, or morpholinyl, wherein the heterocycloalkyl groups are optionally substituted with 1, 2, or 3 groups that are independently halogen, C1-C6 alkyl, C1-C6 alkoxy, hydroxy, hydroxy C1C6 alkyl, C1-C6 alkoxycarbonyl, —CO2H, CF3, or OCF3;
- and
- R20 is C1-C6 alkoxy (preferably C1-C4 alkoxy, more preferably methoxy), or OH.
Dependencies are inferred from the claim text.